JPRN-jRCT2080223587
Completed
Phase 2
A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys with Duchenne Muscular Dystrophy
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- CHUGAI PHARMACEUTICAL CO., LTD.
- Enrollment
- 159
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosed with DMD by a blood test
- •Able to walk without assistance
- •Able to walk up 4 stairs in 8 seconds or less
- •Weigh at least 15 kg (33 lbs)
- •Taking corticosteroids for DMD
- •Other protocol defined Inclusion/Exclusion Criteria could apply.
Exclusion Criteria
- •Any behavior or mental issue that will affect the ability to complete the required study procedures
- •Previously or currently taking medications like androgens or human growth hormone
- •Use of a ventilator during the day
- •Unable to have blood samples collected or receive an injection under the skin
- •Other protocol defined Inclusion/Exclusion Criteria could apply.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular DystrophyDuchenne Muscular DystrophyMedDRA version: 20.0 Level: PT Classification code 10013801 Term: Duchenne muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2016-001654-18-ESBristol-Myers Squibb International Corporation160
Active, not recruiting
Phase 1
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular DystrophyEUCTR2016-001654-18-NLF. Hoffmann-La Roche Ltd166
Active, not recruiting
Phase 1
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular DystrophyEUCTR2016-001654-18-FRBristol-Myers Squibb International Corporation160
Completed
Phase 3
A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys with Duchenne Muscular Dystrophy.Duchenne Muscular DystrophyMuscular Disorder10028396NL-OMON48814Hoffmann-La Roche10
Active, not recruiting
Phase 1
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular DystrophyEUCTR2016-001654-18-GBF. Hoffmann-La Roche Ltd159